VU
NUVL

Valence8 US’s Nuvalent NUVL Stock Holding History

Valence8 US’s Portfolio NUVL Stock Details NUVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,115
Closed -$421K – 47
2024
Q3 		$421K Buy
+4,115
New +$341K 0.17% 26

Other funds holding NUVL

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Valence8 US's NUVL Position: Q4 2024 in Review

Valence8 US sold out of Nuvalent (NUVL) in Q4 2024, closing a stake of 4,115 shares — an estimated $421K sold.

Valence8 US first reported a position in NUVL in Q3 2024 and held it in 1 quarter. The position peaked at $421K in Q3 2024. 216 funds tracked by Wall St. Rank hold NUVL as of Q4 2024.

  • Valence8 US reported no remaining Nuvalent position as of Q4 2024 after selling out during the quarter.
  • Valence8 US sold 4,115 Nuvalent shares in Q4 2024, an estimated $421K.
  • Valence8 US first reported a position in Nuvalent in Q3 2024 and held it in 1 quarter.
  • Valence8 US's Nuvalent position peaked at $421K in Q3 2024.
  • 216 funds tracked by Wall St. Rank held Nuvalent as of Q4 2024.

Based on Valence8 US's 13F filing for Q4 2024, filed 12 Feb 2025.